{
  "symbol": "PRENW",
  "company_name": "Prenetics Global Limited WT",
  "ir_website": "https://ir.prenetics.com/",
  "structured_data": [
    {
      "section_name": "Error Details",
      "links": [
        {
          "title": "This site can’t be reached",
          "url": "https://ir.prenetics.com/",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![logo](/sites/g/files/knoqqb95441/themes/site/nir_pid6545/dist/images/Prenetics_logo_EN.svg) ![logo](/sites/g/files/knoqqb95441/themes/site/nir_pid6545/dist/images/Prenetics_logo_EN.svg) ](https://www.prenetics.com/)\n\n  * [Investors](/investor-relations)\n  * [About Prenetics](/about-prenetics/corporate-profile)\n  * [News & Events](/news-events/press-releases)\n    * [Press Releases](/news-events/press-releases)\n    * [Events](/news-events/events)\n    * [Presentations](/news-events/presentations)\n    * [Media Centre](/news-events/media-centre)\n  * [Stock Performance](/stock-information/stock-quote-chart)\n    * [Stock Quote & Chart](/stock-information/stock-quote-chart)\n    * [Historical Price Lookup](/stock-information/historical-price-lookup)\n    * [Analyst Coverage](/stock-information/analyst-coverage)\n  * [Corporate Governance](/corporate-governance/documents-charters)\n    * [Documents & Charters](/corporate-governance/documents-charters)\n    * [Management & Advisory](/corporate-governance/management-team)\n    * [Board of Directors](/corporate-governance/board-of-directors)\n    * [Committee Composition](/corporate-governance/committee-composition)\n  * [Financials & Filings](/financials-filings/sec-filings)\n    * [SEC Filings](/financials-filings/sec-filings)\n    * [Quarterly Results](/financials-filings/quarterly-results)\n  * [Resources](/ir-resources/investor-faqs)\n    * [Investor FAQs](/ir-resources/investor-faqs)\n    * [Email Alerts](/ir-resources/email-alerts)\n    * [Contact IR](/ir-resources/contact-ir)\n\n\n\n# INVESTOR RELATIONS\n\nPrenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer and clinical health. Our consumer initiative is led by IM8, a new health and wellness brand, and Europa, one of the largest sports distribution companies in the USA. Our clinical division is led by Insighta, our $200 million venture focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for comprehensive genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer comprehensive DNA tests. Each of Prenetics’ units synergistically enhances our global impact on health, embodying our commitment to ‘enhancing life through science’.\n\n  * [Read More](/about-prenetics/corporate-profile)\n\n\n\n[](#profile)\n\n## Stock Information\n\n![Stock Chart](https://api.nasdaqomx.wallst.com/api/chart?theme=narrow&display=mountain&symbol=PRE.O-PRE&scale=linear&duration=1dy&frequency=15min&gridLine=n&bgColor=f4f2f3&lineColor=5daa41&fillcolor=5daa41|ffffff&width=100%&height=340&bdr=2&headerType=&fillOpacity=60&lineSizePrimary=2&volume=0)\n\nMinimum 15 minutes delayed. Source: LSEG\n\n## Press Releases\n\n27 Nov 24\n\n[Prenetics Announces Third Quarter 2024 Financial Results](/news-releases/news-release-details/prenetics-announces-third-quarter-2024-financial-results)\n\nRevenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand Tencent Invests $30 million in Insighta’s Early Cancer Detection Reiterates Revenue Target to Exceed $33 million for FY 2024 CHARLOTTE, N.C., Nov. \n\n18 Nov 24\n\n[Nasdaq-Listed Prenetics and David Beckham Officially Launch IM8 Health](/news-releases/news-release-details/multimedia-update-nasdaq-listed-prenetics-and-david-beckham)\n\nBeckham is a strategic investor in Prenetics and Co-Founding Partner for IM8 IM8 launch marks a bold entry into the $187 billion global consumer health market Launch follows recently announced Prenetics’ acquisition of Europa, one of the largest sports nutrition distributors in the U.S.\n\n15 Oct 24\n\n[Prenetics Announces Tencent’s US$30 Million Investment in Insighta, Strengthening Strategic Partnership for AI-Driven Early Cancer Detection](/news-releases/news-release-details/prenetics-announces-tencents-us30-million-investment-insighta)\n\nHONG KONG, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading health sciences company, today announced that Tencent has made a strategic US$30 million investment in Insighta, a Hong Kong-based early cancer detection company. \n\n07 Oct 24\n\n[Prenetics Announces Second Quarter 2024 Financial Results](/news-releases/news-release-details/prenetics-announces-second-quarter-2024-financial-results)\n\nCost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024 Enters U.S. Health Market in October with IM8, a New Health and Wellness Brand Re-affirms Revenue Target to Exceed US$33 million for FY 2024 CHARLOTTE, N.C., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) \n\n##  Recent Events \n\n[Sidoti Micro Cap Conference](/events/event-details/sidoti-micro-cap-conference)\n\n13 November 2024 at 8:30 a.m. (EST) \n\n[Prenetics CEO Danny Yeung Interviewed by The Wall Street Resource](/events/event-details/prenetics-ceo-danny-yeung-interviewed-wall-street-resource)\n\n19 August 2024 at 4:00 p.m. (EDT) \n\n[Annual General Meeting](/events/event-details/annual-general-meeting)\n\n20 October 2023 at 11:30 a.m. (HKT) \n\n  * [View All Events](/news-events/events)\n\n\n\n##  Featured Reports \n\n[Prenetics Investor Update](/static-files/4cc73d00-21bf-4519-ab4e-4c71c4013b2a)\n\n14 Nov 2024\n\n  * [View All Reports](/news-events/presentations)\n\n\n\nRequest Email Alerts\n\n[](#)\n"
        }
      ]
    }
  ]
}